Abstract
Colon cancer needs better screening and treatment options. Its incidence in the young
population is rising. Recent changes in guidelines recommend beginning screening for
colon cancer at the age of 45. Circulating tumor DNA presents an opportunity to select
patients for administration of adjuvant chemotherapy. Immunotherapy is an option for
patients with a deficiency in mismatch repair proteins. However, its efficacy outside
of this group of patients remains a challenge. Targeted therapies such as BRAF inhibitors
are an option for patients with poor prognosis, for whom cytotoxic chemotherapy is
not as effective. This review presents the recently published evidence regarding screening
and treating patients with colon cancer.
Keywords
Abbreviations:
CC (Colon cancer), NSAIDS (Non-steroidal anti-inflammatory drugs), ctDNA (Circulating tumor DNA), dMMR (Deficient mismatch repair), MSI (Microsatellite instability), FOLFOX (5-Fluorouracil Oxaliplatin), CAPEOX (Capecitabine Oxaliplatin), FOLFIRI (5-fluorouracil irinotecan)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Colorectal CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
REFERENCES
American Cancer Society. 2022. Available at: https://www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html, Accessed date 06/01/2022.
- Colorectal cancer statistics, 2020.Ca Cancer J Clin. 2020; 70: 145-164https://doi.org/10.3322/caac.21601
- Colorectal cancer.Lancet. 2019; 394: 1467-1480https://doi.org/10.1016/s0140-6736(19)32319-0
- Colorectal cancer in the young: epidemiology, prevention, management.Am Soc Clin Oncol Educ Book. 2020; 40: e75-e88https://doi.org/10.1200/edbk_279901
- Colorectal cancer: a disease of the young?.Lancet Oncol. 2017; 18: 413https://doi.org/10.1016/s1470-2045(17)30202-4
- Screening for colorectal cancer.JAMA. 2021; 325: 1965-1977https://doi.org/10.1001/jama.2021.6238
- Screening for colorectal cancer.JAMA. 2021; 325: 1978-1997https://doi.org/10.1001/jama.2021.4417
- Survival in young-onset metastatic colorectal cancer: findings from cancer and Leukemia Group B (Alliance)/SWOG 80405.J Natl Cancer Inst. 2021; 114: 427-435https://doi.org/10.1093/jnci/djab200
- Impact of patient factors on recurrence risk and time dependency of oxaliplatin benefit in patients with colon cancer: analysis from modern-era adjuvant studies in the adjuvant colon cancer end points (ACCENT) database.J Clin Oncol. 2016; 34: 843-853https://doi.org/10.1200/jco.2015.63.0558
- Clinicopathological and molecular characteristics of early-onset stage iii colon adenocarcinoma: an analysis of the ACCENT database.J Natl Cancer Inst. 2021; 113: 1693-1704https://doi.org/10.1093/jnci/djab123
- Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.New Engl J Medicine. 2004; 350: 2343-2351https://doi.org/10.1056/nejmoa032709
- Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants.JAMA. 2015; 313: 1133-1142https://doi.org/10.1001/jama.2015.1815
- Effect of celecoxib vs placebo added to standard adjuvant therapy on disease-free survival among patients with stage iii colon cancer: the CALGB/SWOG 80702 (Alliance) randomized clinical trial.JAMA. 2021; 325: 1277-1286https://doi.org/10.1001/jama.2021.2454
- Duration of adjuvant chemotherapy for stage iii colon cancer.New Engl J Medicine. 2018; 378: 1177-1188https://doi.org/10.1056/nejmoa1713709
- Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial.Ann Oncol. 2021; 32: 77-84https://doi.org/10.1016/j.annonc.2020.10.480
- Assessment of duration and effects of 3 vs 6 months of adjuvant chemotherapy in high-risk stage ii colorectal cancer.Jama Oncol. 2020; 6: 547-551https://doi.org/10.1001/jamaoncol.2019.6486
- Circulating Tumor DNA as a prognostic marker in stage iii colon cancer.Jama Oncol. 2020; 6: 932https://doi.org/10.1001/jamaoncol.2020.0283
- Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan.J Clin Oncol. 2022; 40: 9https://doi.org/10.1200/jco.2022.40.4_suppl.009
- Prognostic impact of early treatment discontinuation and early oxaliplatin discontinuation in patients treated with 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 trials.J Clin Oncol. 2022; 40: 11https://doi.org/10.1200/jco.2022.40.4_suppl.011
- O-8 Final overall survival for the phase 3 KN177 study: pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer.Ann Oncol. 2021; 32: S220-S221https://doi.org/10.1016/j.annonc.2021.05.012
- Encorafenib plus cetuximab as a new standard of care for previously treated braf v600e-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study.J Clin Oncol. 2021; 39: 273-284https://doi.org/10.1200/jco.20.02088
- KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer.J Clin Oncol. 2021; 39: 6https://doi.org/10.1200/jco.2021.39.3_suppl.6
- Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.Lancet Oncol. 2021; 22: 665-677https://doi.org/10.1016/s1470-2045(21)00064-4
- First-Line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II checkMate 142 study.J Clin Oncol. 2021; 40: 161-170https://doi.org/10.1200/jco.21.01015
- NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study-a randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA misma.J Clin Oncol. 2021; 39https://doi.org/10.1200/jco.2021.39.3-suppl.tps158
- Nivolumab (NIVO) + 5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): phase 2 results from checkMate 9X8.J Clin Oncol. 2022; 40: 8https://doi.org/10.1200/jco.2022.40.4_suppl.008
- Prevalence of RAS and BRAF mutations in metastatic colorectal cancer (mCRC) patients by tumor location.J Clin Oncol. 2018; 36: 681https://doi.org/10.1200/jco.2018.36.4_suppl.681
- Mutations of the BRAF gene in human cancer.Nature. 2002; 417: 949-954https://doi.org/10.1038/nature00766
- BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).J Clin Oncol. 2022; 40: TPS211https://doi.org/10.1200/jco.2022.40.4_suppl.tps211
- K-ras mutations and benefit from cetuximab in advanced colorectal cancer.New Engl J Medicine. 2008; 359: 1757-1765https://doi.org/10.1056/nejmoa0804385
- Sotorasib for previously treated colorectal cancers with KRAS G12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.Lancet Oncol. 2022; 23: 115-124https://doi.org/10.1016/s1470-2045(21)00605-7
- First-in-human phase i/ib dose-finding study of adagrasib (mrtx849) in patients with advanced kras g12c solid tumors (KRYSTAL-1) [e-pub ahead of print].J Clin Oncol. 2022; https://doi.org/10.1200/jco.21.02752
- Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.Ann Oncol. 2018; 29: 1108-1119https://doi.org/10.1093/annonc/mdy100
- Long-term clinical outcome of trastuzumab and lapatinib for her2-positive metastatic colorectal cancer.Clin Colorectal Canc. 2020; 19: 256-262.e2https://doi.org/10.1016/j.clcc.2020.06.009
- MOUNTAINEER:open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress).J Clin Oncol. 2021; 39: TPS153https://doi.org/10.1200/jco.2021.39.3_suppl.tps153
- Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.Lancet Oncol. 2021; 22: 779-789https://doi.org/10.1016/s1470-2045(21)00086-3
- Anlotinib monotherapy for refractory metastatic colorectal cancer: a double-blinded, placebo-controlled, randomized phase III trial (ALTER0703).Oncol. 2021; 26: e1693-e1703https://doi.org/10.1002/onco.13857
- The efficacy and safety of anlotinibin refractory colorectal cancer: adouble-blinded, placebocontrolled, randomized phase IIIALTER0703 trial.J Clin Oncol. 2021; 39: 65https://doi.org/10.1200/jco.2021.39.3_suppl.65
- FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer.Future Oncol. 2021; 17: 3151-3162https://doi.org/10.2217/fon-2021-0202
- FRESCO-2: a global phase III study of the efficacy and safety offruquintinib in patients (pts) withmetastatic colorectal cancer(mCRC).J Clin Oncol. 2021; 39https://doi.org/10.1200/jco.2021.39.3-suppl.tps154
- XELOX/XELIRI alternative regimen as first-line treatment of metastatic colorectal cancer (CCRCTO-2: TROT): a phase II study.Ann Oncol. 2021; : 32https://doi.org/10.1016/j.annonc.2021.08.940
- Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch colorectal cancer group.Lancet. 2015; 385: 1843-1852https://doi.org/10.1016/s0140-6736(14)62004-3
- Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.Lancet Oncol. 2015; 16: 1355-1369https://doi.org/10.1016/s1470-2045(15)00042-x
- Capecitabine versus active monitoring in stable or responding metastatic colorectal cancer after 16 weeks of first-line therapy: results of the Randomized FOCUS4-N Trial.J Clin Oncol. 2021; 39: 3693-3704https://doi.org/10.1200/jco.21.01436
- Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: first results of the randomized phase II TIME-PRODIGE28 UNICANCER study according to RAS/BRAF status.Ann Oncol. 2021; 32: S548-S549https://doi.org/10.1016/j.annonc.2021.08.950
- Maintenance treatment withcetuximab versus observation in RAS wild-type metastaticcolorectal cancer: results of therandomized phase II PRODIGE 28-time UNICANCER study.J Clin Oncol. 2021; 39: 15https://doi.org/10.1200/jco.2021.39.3_suppl.15
- Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.Lancet Oncol. 2021; 22: 256-266https://doi.org/10.1016/s1470-2045(20)30599-4
Article Info
Publication History
Published online: June 03, 2022
Accepted:
May 31,
2022
Received in revised form:
May 26,
2022
Received:
March 30,
2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
